Real-World Evidence: Sleep Latency, Nocturnal Awakenings & Minor Cannabinoids (CBN/CBG) across 24,000+ Visits
CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 16, 2026 Real-World Evidence: Sleep Latency, Nocturnal Awakenings & Minor Cannabinoids (CBN/CBG) across 24,000+ Visits Longitudinal…
Cannabinoids & Antidepressants & SSRIs / SNRIs: Evidence, Pharmacokinetics & Safety Review
Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Antidepressants & SSRIs / SNRIs: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine &…
CBD Gummies and Psychosis: What the Evidence Shows for Everyday Use
CBD gummies and psychosis risk remain an area with limited and contradictory evidence. Clinicians must assess psychosis risk carefully when counseling patients using CBD gummies. Understanding the clinical evidence on CBD gummies and psychosis risk is…
Does CBD Gummies Make You Sleepy? What the Evidence and Experience Actually Show
CBD gummies sleep effects vary depending on dose and ingredients. Evidence shows that typical CBD gummy doses may promote alertness rather than sedation. Experience suggests added ingredients often contribute to sleepiness more than CBD itself.
Low-Dose CBD and Therapeutic Value: What the New Clinical Pharmacology Review Found
A review in the British Journal of Clinical Pharmacology evaluated the pharmacokinetics, efficacy, and safety of low-dose cannabidiol. Dr. Caplan reviews this low dose CBD pharmacokinetics safety research and what it adds beyond behavioral-effect…
Week in Review: Clinical Breakthroughs in Metabolism, Cannabinoids, Primary Care, and AI (10/9 – 10/16/26)
Clinical Evidence Radar The Medical Frontier: Week in Review (10/9 – 10/16/26) Evidence-grounded briefing ordered dynamically by clinician impact index, practice utility, and patient resonance. ⚡ Executive Clinical Evidence Summary (2026 Direct Takeaway)…
Can CBD Gummies Cause Psychosis? – Clinical Insights
CBD gummies psychosis clinical insights highlight the importance of patient screening and product quality. Emerging case reports raise questions about CBD's safety in vulnerable individuals. Clinicians must consider these insights when recommending…
Mabewo Phytopharm Targets Inflammatory Pain and Arthritis with Proprietary Cannabinoid Formulations
The patent application describes a specialized cannabinoid composition engineered specifically to manage pain and inflammatory disorders, including arthritis. Leveraging defined botanical extracts from the Cannabaceae family alongside specific…
Real-World Evidence: Pediatric Neurodevelopment & Behavioral Dysregulation in Physician-Co-Managed Cohorts
CED Clinic Clinical Registry Real-World Evidence (RWE) CEBM Level 2B: Clinical Registry Cohort Published: October 16, 2026 Real-World Evidence: Pediatric Neurodevelopment & Behavioral Dysregulation in Physician-Co-Managed Cohorts Observational…
New Cannabis Cultivar 4D2 Secures Patent for Varin and Classical Cannabinoids
The patent disclosure protects a proprietary annual herbaceous cannabis variety, designated '4D2', created through sexual hybridization. The cultivar is chemically distinguished by its simultaneous production of four key cannabinoids:…
